Want to see RIGL full AI Analyst Report?
RIGL Stock Chart & Stats
$32.43
-$0.99(-5.79%)
At close: 4:00 PM EST
$32.43
-$0.99(-5.79%)
Day’s Range― - ―
52-Week Range$18.80 - $52.24
Previous CloseN/A
Volume99.93K
Average Volume (3M)372.78K
Market Cap
$750.07M
Enterprise Value$431.35
Total Cash (Recent Filing)$146.68M
Total Debt (Recent Filing)$45.72M
Price to Earnings (P/E)2.0
Beta1.88
Next Earnings
Aug 04, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)20.07
Shares Outstanding18,502,080
10 Day Avg. Volume376,340
30 Day Avg. Volume372,777
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.97
Price to Sales (P/S)2.62
P/FCF Ratio10.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$59.33Price Target Upside82.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)3
Revenue Forecast (FY)$276.60M
Bulls Say, Bears Say
Bulls Say
Sustained Product Revenue GrowthConsistent double-digit growth across core marketed products demonstrates durable commercial traction and prescriber adoption. Sustained strength at TAVALISSE and REZLIDHIA builds a recurring revenue base, improves bargaining power with payers, and supports multi-quarter revenue visibility for reinvestment and expansion.
Improved Cash Generation & ProfitabilityConversion to positive operating and free cash flow alongside a sharp revenue and earnings inflection materially strengthens financial flexibility. Positive cash generation supports runway for development, BD, and commercialization, though continued monitoring of cash conversion relative to reported net income is warranted for durability.
Pipeline & BD Expansion (VEPPANU Deal)Acquiring global rights to VEPPANU meaningfully expands Rigel's oncology pipeline and potential commercial runway, leveraging existing commercial infrastructure. The deal provides structured upside via milestones/royalties while positioning the company to capture long-term value from a late-stage oncology asset.
Bears Say
Historical Balance-Sheet FragilityAlthough leverage is conservative today, the company's recent history of negative equity and rapid swings in leverage indicates balance-sheet vulnerability. For a biotech with milestone-driven cash flows, prior fragility increases refinancing and liquidity risks if revenue or cash generation weakens, limiting strategic flexibility.
Portfolio Concentration & GAVRETO PlateauOne franchise exhibiting low single-digit growth and a quarterly plateau highlights concentration risk: material revenue depends on a few products. Slower GAVRETO upside constrains overall growth optionality and increases reliance on continued strong performance from TAVALISSE/REZLIDHIA and BD success to sustain revenues beyond current levels.
Loss Of Partner Support (Lilly Termination)Termination of the Lilly collaboration removes external funding and development support for the RIPK1 program, forcing Rigel to fund or reprioritize the asset. Loss of partner milestones and shared resources increases program-level execution risk and could divert capital or management focus from other strategic priorities.
Rigel News
RIGL FAQ
What was Rigel Pharmaceuticals’s price range in the past 12 months?
Rigel Pharmaceuticals lowest stock price was $18.80 and its highest was $52.24 in the past 12 months.
What is Rigel Pharmaceuticals’s market cap?
Rigel Pharmaceuticals’s market cap is $750.07M.
When is Rigel Pharmaceuticals’s upcoming earnings report date?
Rigel Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 14 days.
How were Rigel Pharmaceuticals’s earnings last quarter?
Rigel Pharmaceuticals released its earnings results on May 05, 2026. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.795 by -$0.355.
Is Rigel Pharmaceuticals overvalued?
According to Wall Street analysts Rigel Pharmaceuticals’s price is currently Undervalued.
Does Rigel Pharmaceuticals pay dividends?
Rigel Pharmaceuticals does not currently pay dividends.
What is Rigel Pharmaceuticals’s EPS estimate?
Rigel Pharmaceuticals’s EPS estimate is 0.14.
How many shares outstanding does Rigel Pharmaceuticals have?
Rigel Pharmaceuticals has 18,502,080 shares outstanding.
What happened to Rigel Pharmaceuticals’s price movement after its last earnings report?
Rigel Pharmaceuticals reported an EPS of $0.44 in its last earnings report, missing expectations of $0.795. Following the earnings report the stock price went down -5.055%.
Which hedge fund is a major shareholder of Rigel Pharmaceuticals?
Currently, no hedge funds are holding shares in RIGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rigel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$59.33 (82.96% Upside)
$59.33 (82.96% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 59.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
186.75%
Trailing 12-Months
Company Description
Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Stock 12 Month Forecast
Average Price Target
$59.33
▲(82.96% Upside)
Technical Analysis
Ownership Overview
3.34% Insiders
29.26% Mutual Funds
0.47% Other Institutional Investors
44.77% Public Companies and
Individual Investors